Axsome Therapeutics Is Maintained at Outperform by RBC Capital
Axsome Therapeutics Analyst Ratings
RBC Lifts Price Target on Axsome Therapeutics to $131 From $130, Keeps Outperform Rating
Wells Fargo Maintains Axsome Therapeutics(AXSM.US) With Buy Rating, Maintains Target Price $140
Buy Rating Justified for Axsome Therapeutics Amidst Strong Market Opportunities and Promising Trial Outcomes
Mizuho Securities Maintains Axsome Therapeutics(AXSM.US) With Buy Rating
Analysts Offer Insights on Healthcare Companies: Establishment Labs Holdings (ESTA), Alkermes (ALKS) and Axsome Therapeutics (AXSM)
Mizuho Securities Maintains Axsome Therapeutics(AXSM.US) With Buy Rating, Maintains Target Price $106
RBC Capital Maintains Axsome Therapeutics(AXSM.US) With Buy Rating, Maintains Target Price $130
RBC Capital Sticks to Their Buy Rating for Axsome Therapeutics (AXSM)
TD Cowen Maintains Axsome Therapeutics(AXSM.US) With Buy Rating, Maintains Target Price $120
Morgan Stanley Maintains Axsome Therapeutics(AXSM.US) With Buy Rating, Maintains Target Price $115
Mizuho Securities Maintains Axsome Therapeutics(AXSM.US) With Buy Rating, Maintains Target Price $106
Axsome Therapeutics Analyst Ratings
Axsome Therapeutics (AXSM) Gets a Buy From Cantor Fitzgerald
HC Wainwright & Co. Reiterates Buy on Axsome Therapeutics, Maintains $180 Price Target
Needham Maintains Axsome Therapeutics(AXSM.US) With Buy Rating, Maintains Target Price $130
H.C. Wainwright Maintains Axsome Therapeutics(AXSM.US) With Buy Rating, Maintains Target Price $180
Buy Rating Affirmed for Axsome Therapeutics on Robust Pipeline and Promising Regulatory Prospects
Buy Rating Affirmed for Axsome Therapeutics on Strong Pipeline and Promising Drug Trials